the psychiatric community would jump for joy for a really good non-stimulant AHDH drug, it would be a very big deal. A very big drug. CX-1739.....who knows but I'll bet if it runs trials in the 3rd quarter there will be anticipation and a much higher stock price. They nailed the "reliable" animal tests, good phase 2a data and it's a $4-5 stock, you catch my drift why this .59 is such a joke?